Use of common analgesic medications and ovarian cancer survival: Results from a pooled analysis in the Ovarian Cancer Association Consortium Journal Article
| Authors: | Dixon, S. C.; Nagle, C. M.; Wentzensen, N.; Trabert, B.; Beeghly-Fadiel, A.; Schildkraut, J. M.; Moysich, K. B.; deFazio, A.; Risch, H. A.; Rossing, M. A.; Doherty, J. A.; Wicklund, K. G.; Goodman, M. T.; Modugno, F.; Ness, R. B.; Edwards, R. P.; Jensen, A.; Kjaer, S. K.; Hogdall, E.; Berchuck, A.; Cramer, D. W.; Terry, K. L.; Poole, E. M.; Bandera, E. V.; Paddock, L. E.; Anton-Culver, H.; Ziogas, A.; Menon, U.; Gayther, S. A.; Ramus, S. J.; Gentry-Maharaj, A.; Pearce, C. L.; Wu, A. H.; Pike, M. C.; Webb, P. M.; on behalf of the Ovarian Cancer Association Consortium |
| Article Title: | Use of common analgesic medications and ovarian cancer survival: Results from a pooled analysis in the Ovarian Cancer Association Consortium |
| Abstract: | Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited. Methods: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths). Results: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)). Conclusions: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted. |
| Keywords: | survival; ovarian cancer; paracetamol; diagnosis; acetaminophen; metaanalysis; pooled analysis; aspirin; nonsteroidal antiinflammatory drugs; nonsteroidal anti-inflammatory drugs; nsaid |
| Journal Title: | British Journal of Cancer |
| Volume: | 116 |
| Issue: | 9 |
| ISSN: | 0007-0920 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2017-04-25 |
| Start Page: | 1223 |
| End Page: | 1228 |
| Language: | English |
| ACCESSION: | WOS:000400128100014 |
| DOI: | 10.1038/bjc.2017.68 |
| PROVIDER: | wos |
| PMCID: | PMC5418444 |
| PUBMED: | 28350790 |
| Notes: | Article -- Source: Wos |
